Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Pharmaceutical 93

Pharmaceutical

AZ corona Vaccine trial | Merck and Gilead Deal

Notizia - Recent Pharma, Healthcare and Biotech Happenings

While AZ resumes its COVID-19 vaccine trial in the UK; Merck and Gilead are busy making sizeable Breast cancer deals

AstraZeneca/ Oxford resumes the trial of their COVID-19 vaccine in the UK After receiving a go-ahead from the UK’s Medicines Health Regulatory Authority, AstraZeneca and the University of Oxford have resumed the trials of their experimental coronavirus candidate AZD1222 in the country. A rapid review by the trial’s independent safety review committee and national regulators has stamped upon the safety and efficacy of the vaccine needed to proceed further. However, the studies in the US remains halted. The duo had to suspend the trials a week ago after a patient got critically ill. The company still has not disclosed any further information and labelled the condi...

Explore More...

Business Cocktail

‘Killer’ Mosquito to be released in 20 US states to fight mosquitoes

Personalized Medicine

Teva sells generics; Valeant trades; Roche’s Genentech; J&J’s next potential frontier

WAS

Wiskott – Aldrich syndrome – a rare X-linked disorder

Notizia

AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes

Metachromatic Leukodystrophy (MLD): A Rare Indication with great unmet medical need

Wet AMD: A chronic eye condition with promising therapies

Publishers collaborate to remove journal articles from ResearchGate

Novo petitions FDA;J&J invests; Xarelto’s trial; Roche’s Tecentriq

Natural Killer Cell Therapies– Advancing technology increasing competition among the companies

C-X-C Chemokine Receptor Inhibitors–The Emerging Therapeutic Agents

Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal

Notizia

Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval

Isocitrate dehydrogenase (IDH) inhibitors– Emerging Anti-Cancer Therapeutics

Thrombolytic Sciences’ trial; NurOwn for ALS; Biosimilar receives approval; Trelegy Ellipta for the treatment of COPD

Oral Mucositis – A Common Cancer Therapy Adverse Reaction

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly